Integrating Dapagliflozin and Sitagliptin FDC for Optimizing Outcomes in Type-2 Diabetes with Cardiometabolic-Based Chronic Disease (CMBCD) patients – Dr Kaushik Biswas

Introduction
India’s T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a significant cardio-metabolic risk burden (1). The CMBCD framework highlights the interrelated pathophysiology of hyperglycaemia, obesity, CVD, and renal dysfunction, which is increasingly used to conceptualize T2DM (2). Multifactorial approaches aimed at reducing cardiometabolic risk are replacing traditional glucose-centric therapy paradigms. SGLT2i and DPP-4i are two pharmacological classes of glucose-lowering agents with over a decade of experience for their gluco-metabolic and cardio-renal effects. Among these, sitagliptin (DPP-4i) and dapagliflozin (SGLT2i) have been extensively studied both separately and together to improve glycaemic management and address cardiometabolic risk factors (3,4). The combination potentially aligns with the CMBCD approach, promoting sustained glycaemic & weight control with improved cardio-renal outcomes.
Rationale for Combination Therapy with Dapagliflozin and Sitagliptin FDC in the context of CMBCD in T2D Care paradigm
The combination of Dapagliflozin and Sitagliptin FDC, provides a mechanistically complementary strategy for improving glycaemic and cardiometabolic outcomes. Dapagliflozin lowers plasma glucose by blocking renal SGLT2 transporters in the proximal tubule, which promotes urine glucose excretion via an insulin-independent mechanism. This predominantly lowers FPG fasting plasma glucose and has been linked to weight loss and reductions in systolic blood pressure due to osmotic diuresis. Sitagliptin, on the other hand, increases incretin activity by blocking the DPP-4 enzyme, allowing incretin hormones like GLP-1 and GIP to prolong their action. This stimulates glucose-dependent insulin secretion while suppressing glucagon, primarily improving postprandial glucose levels (5,6). By targeting both fasting and postprandial hyperglycaemia, these agents offer additive glycaemic control compared to either agent alone (7). Importantly, by addressing larger cardiometabolic concerns, this combination also conforms to the CMBCD framework. Sitagliptin promotes better β-cell preservation and metabolic stability, while dapagliflozin has shown notable cardiovascular and renal protective advantages, such as decreased hospitalization for heart failure and slowed progression of chronic kidney disease. (8).
 Table 1: Dapagliflozin and Sitagliptin FDC – Combining Complementary Effects for Cardio-Metabolic Care in T2D
Dapagliflozin and Sitagliptin FDC: Clinical Evidence Review
SGLT2i Improve VAT – Key Metabolic Outcome -2026 Update: SGLT-2 inhibitors promote lipolysis, a significant reduction in visceral adipose tissue (VAT) compared with placebo (SMD −0.66; 95% CI −1.22 to −0.10). Suggesting activation of the liver–brain–adipose axis and glycogen depletion signalling, shifting metabolism toward fat utilization and reducing adipose tissue accumulation (9).
SGLT2i on Cardio Renal Outcomes: SGLT2 Inhibitors outperform in cardiorenal outcomes, a systematic review and network meta-analysis conducted to compare the effects of SGLT-2i vs GLP-1RA on the heart and kidneys in individuals with T2D and Cardio-renal disease. 13 RCTs with 32,949 patients were included in the study. When compared to a placebo, the results demonstrated that SGLT-2i significantly decreased severe adverse CV events (RR 0.85; 95% CI 0.75–0.96) and renal outcomes (RR 0.68; 95% CI 0.59–0.78). While there were no statistically significant differences in the two classes’ primary CV outcomes, SGLT-2i showed better renal protection in indirect comparisons when compared to GLP-1RA (8).
Dapagliflozin and Sitagliptin FDC- Gluco-Cardio-Metabolic Benefits: A guidance-based analysis including 98 cardiologists from seven advisory board meetings in India assessed evidence supporting the use of Dapagliflozin and Sitagliptin FDC to address T2D. A review of clinical and Indian real-world studies found that the combination significantly improved HbA1c, fasting and postprandial glucose, body weight, blood pressure, and lipid parameters, indicating benefits in glycaemic control and cardiometabolic risk reduction (10).
A clinical survey (DISI Study) reaffirmed that among the available SGLT2i/DPP4i combinations, the Dapagliflozin Sitagliptin FDC is preferred as therapy in Indian clinical settings for its cardiometabolic benefits (11).
Considering Dapagliflozin & Sitagliptin: Guideline Recommendations
• The most recent NICE 2026 guidelines (NG28), emphasises that SGLT2-i should be used as an early therapy in T2D management, or when metformin is not tolerated. Moreover, DPP-4i are also included in this class-based guideline for glycaemic management in T2D (12).
• According to the latest March 2026 published iCARDIO Alliance recommendations on diabetes management published in the Journal of the Association of Physicians of India, dapagliflozin is preferred in T2D with CV risk due to its cardioprotective and HF benefits, whereas sitagliptin is primarily used for glycaemic control with cardiovascular safety (13).
• The ADA Standards of Care in Diabetes—2026, suggest SGLT2-i for T2D, particularly in patients with CVD, HF, or CRD due to their cardiorenal benefits. At the same time DPP-4 i, are also included as glucose-lowering options with weight-neutral effects and established cardiovascular safety (14).
Safety profile
The combination therapy of Dapagliflozin and Sitagliptin FDC exhibits a good safety and tolerability profile, which is mostly consistent with the known safety features of the individual medication classes (15).
Key Messages
1. The CMBCD paradigm emphasizes comprehensive T2DM therapy targeting metabolic, cardiovascular, and renal risks.
2. Dapagliflozin and Sitagliptin FDC have complementary mechanisms: SGLT2 inhibition increases urinary glucose excretion, while DPP-4 inhibition enhances incretin activity, improving glycaemic control. Most recently, SGLT2i have been proven to reduce VAT, an important metabolic benefit.
3. Clinical data show that combination therapy significantly reduces HbA1c, fasting, and postprandial glucose in inadequately controlled T2D patients, with a favourable safety profile.
4. Beyond glycaemic control, the combination improves weight, blood pressure, and cardiometabolic risk, aligning with CMBCD goals (16), and is widely accepted by Indian clinicians (11).
Abbreviations
T2D- Type 2 Diabetes, SGLT-2 i- Sodium Glucose Co-transporter-2 inhibitor, DPP-4i- Dipeptidly Peptidase-4 inhibitors, BP- Blood Pressure, CMBCD- Cardiometabolic-based chronic disease, CVD- Cardiovascular Disease, CRD- Chronic Renal Disease, GLP-1 – Glucagon-like Peptide-1, GIP- Glucose-dependent Insulinotropic Polypeptide, HF- Heart failure, HbA1c – Glycated, Hemoglobin, NICE guideline – National Institute for Health and Care Excellence Guidelines, FDC – Fixed Dose Combination, VAT-Visceral Adipose Tissue, DAPSI study – Dapagliflozin + Sitagliptin, RCT- Randomised Controlled Trials, ICARDIO alliance- International Cardiometabolic alliance